Company intelligence / Profile preview
Temple Therapeutics
Geleen, Netherlandstemplerx.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Temple Therapeutics has completed a groundbreaking human trial for TTX333, which addresses post-surgical adhesions. The company is advancing this therapy through Phase 3 clinical trials for use in gynecological surgeries.
- Therapeutic areas
- OtherWomen's HealthOncology
- Modalities
- Monoclonal antibodyNovel therapeutics
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Temple Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Temple Therapeutics.